» Articles » PMID: 31269957

Cathepsin L-induced Galectin-1 May Act As a Proangiogenic Factor in the Metastasis of High-grade Serous Carcinoma

Abstract

Background: New treatment options for metastasised high-grade serous carcinoma (HGSC) are urgently needed. HGSC frequently metastasises to the omentum, inducing angiogenesis in the local omental microvasculature to facilitate tumour growth. We previously showed that HGSC-secreted cathepsin L (CathL) induces pro-angiogenic changes in disease relevant human omental microvascular endothelial cells (HOMECs), suggesting a role in tumour angiogenesis. Here we investigate whether CathL acts by inducing local production of the carbohydrate-binding protein galectin-1 (Gal1), which has been reported to be involved in tumourigenesis in other tumours.

Methods: HOMECs were used for all experiments. Gal1 mRNA and protein levels were measured by RT-PCR and ELISA respectively. Gal1-induced cell proliferation was assessed using WST-1 assay, migration using a transwell assay and in vivo Gal1 expression by immunohistochemistry.

Results: CathL transcriptionally regulated HOMEC production and secretion of Gal1 via activation of NFκB (significantly inhibited by sulfasalazine). Gal1 significantly enhanced HOMEC migration (p < 0.001) and proliferation (p < 0.001), suggesting an autocrine action. The latter was significantly reduced by the MEK/ERK1/2 inhibitors U0126 and PD98059 suggesting downstream activation of this pathway. Immunohistochemical analysis of omenta from HGSC patients with or without metastatic disease demonstrated a positive correlation between Gal1 expression and number of microvessels (r = 0.8702, p < 0.001), and area of vessels (r = 0.7283, p < 0.001), supporting a proangiogenic role for Gal1 in omental metastases.

Conclusion: HOMEC Gal1 transcription and release in response to CathL secreted from metastasising HGSC acts in an autocrine manner on the local microvasculature to induce pro-angiogenic changes, highlighting a potential new therapeutic target.

Citing Articles

Obesity-driven changes in breast tissue exhibit a pro-angiogenic extracellular matrix signature.

Bamberg E, Maslanka M, Vinod-Paul K, Sams S, Pollack E, Conklin M Matrix Biol Plus. 2024; 24:100162.

PMID: 39380725 PMC: 11460480. DOI: 10.1016/j.mbplus.2024.100162.


The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.

Garlisi B, Lauks S, Aitken C, Ogilvie L, Lockington C, Petrik D Curr Oncol. 2024; 31(7):3826-3844.

PMID: 39057155 PMC: 11275383. DOI: 10.3390/curroncol31070283.


Vascular galectins in tumor angiogenesis and cancer immunity.

Thijssen V Semin Immunopathol. 2024; 46(1-2):3.

PMID: 38990363 PMC: 11239785. DOI: 10.1007/s00281-024-01014-9.


Identification of the genetic characteristics of copy number variations in experimental specific pathogen-free ducks using whole-genome resequencing.

Li L, Quan J, Liu H, Yu H, Chen H, Xia C BMC Genomics. 2024; 25(1):17.

PMID: 38166615 PMC: 10759622. DOI: 10.1186/s12864-023-09928-8.


Lysosomes, curcumin, and anti-tumor effects: how are they linked?.

Shen Q, Pan X, Li Y, Li J, Zhang C, Jiang X Front Pharmacol. 2023; 14:1220983.

PMID: 37484013 PMC: 10359997. DOI: 10.3389/fphar.2023.1220983.


References
1.
Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S . Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients. Int J Mol Sci. 2017; 18(6). PMC: 5486053. DOI: 10.3390/ijms18061230. View

2.
Ito K, Scott S, Cutler S, Dong L, Neuzil J, Blanchard H . Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis. 2011; 14(3):293-307. PMC: 3155035. DOI: 10.1007/s10456-011-9213-5. View

3.
Kukreja I, Kapoor P, Deshmukh R, Kulkarni V . VEGF and CD 34: A correlation between tumor angiogenesis and microvessel density-an immunohistochemical study. J Oral Maxillofac Pathol. 2014; 17(3):367-73. PMC: 3927337. DOI: 10.4103/0973-029X.125200. View

4.
Chiariotti L, Berlingieri M, Battaglia C, Benvenuto G, Martelli M, Salvatore P . Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer. 1995; 64(3):171-5. DOI: 10.1002/ijc.2910640305. View

5.
Orozco C, Martinez-Bosch N, Guerrero P, Vinaixa J, DAlotto-Moreno T, Iglesias M . Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A. 2018; 115(16):E3769-E3778. PMC: 5910865. DOI: 10.1073/pnas.1722434115. View